Neonates with high risk factors for hearing loss have a prevalence of up to 40% (Vignesh, Jaya, & Muraleedharan 2016).

[3] Diagnosis is possible after a test battery, that must necessarily include the following: the auditory brainstem response and otoacoustic emissions.

Auditory brainstem response should be tested with both polarities (helps in identifying cochlear microphonics).

[8] FM systems in combination with hearing aids or cochlear implants could increase success of these amplification devices.

An ABR (auditory brainstem response) is required to assess that the sound is successfully transmitted through the nerve to the brain.

In most parts of Australia, hearing screening via ABR testing is mandated, meaning that essentially all congenital (i.e., not those related to later onset degenerative disorders) auditory neuropathy cases should be diagnosed at birth.